DengYue Medicine (DengYueMed/Hong Kong Dengyue Pharmaceutical Limited), founded in 2019, is located in Hong Kong SAR. DengYue is licensed by the Department of Health of Hong Kong to take photos of pharmaceutical import and export wholesalers, specializing in the import and export of new and specialty drugs as well as isolated drugs in the field of major chronic diseases.
-
5 Postari
-
1 Fotografii
-
0 Video
-
DengYueMed/Hong Kong Dengyue Pharmaceutical Limited la 6/F, Tai Tak Industrial Building, New Territories, Hong Kong
-
Studiat Pharmaceutical Sciences la The Chinese University of Hong KongClass of 2018
-
08/09/2005
-
Urmarit de 0 people
Recent Actualizat
-
El Boom de los Fármacos Innovadores Chinos en el Mercado Global: DengYue Medicine se Une a los Líderes de la ExportaciónEn un año marcado por avances sin precedentes en la biotecnología, China se consolida como una potencia en la exportación de fármacos innovadores. Según informes recientes, las transacciones de salida de medicamentos innovadores chinos alcanzaron casi los 66 mil millones de dólares en la primera mitad de 2025, superando los totales anuales de...0 Commentarii 0 Distribuiri 115 Views 0 previzualizareVă rugăm să vă autentificați pentru a vă dori, partaja și comenta!
-
China’s Pharmaceutical Exports Show New Momentum Amid Global Trade ShiftsThe landscape of China’s pharmaceutical exports is entering a period of accelerated transformation, driven by changing global trade patterns, the rise of innovative drug development, and the diversification of global healthcare demand. In the past decade, China’s pharmaceutical exports were dominated by active pharmaceutical ingredients (APIs) and intermediate chemicals. Today,...0 Commentarii 0 Distribuiri 456 Views 0 previzualizare
-
Flyrcado™ : A Breakthrough In Cardiac PET Imaging For Coronary Artery DiseaseIn a landmark advancement for nuclear cardiology, GE HealthCare has launched Flyrcado™ (flurpiridaz F 18), the first FDA-approved unit-dose positron emission tomography (PET) myocardial perfusion imaging (MPI) agent for detecting coronary artery disease (CAD). Approved in September 2024 and commercially available in select U.S. markets...0 Commentarii 0 Distribuiri 582 Views 0 previzualizare
-
Ionis Launches Tryngolza™ (Olezarsen) for FCS With Positive Phase 3 Data and $595,000 Annual List PriceIonis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced the official U.S. launch of Tryngolza™ (olezarsen), a novel, once-monthly RNA-targeted therapy for familial chylomicronemia syndrome (FCS). The drug enters the market at an annual list price of $595,000, following its FDA approval in December 2024. First FDA-Approved Olezarsen Therapy for...0 Commentarii 0 Distribuiri 687 Views 0 previzualizare
-
0 Commentarii 0 Distribuiri 250 Views 0 previzualizare
Mai multe povesti
Sponsor